Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia
Authors
Keywords
-
Journal
Journal of Translational Medicine
Volume 10, Issue 1, Pages 178
Publisher
Springer Nature
Online
2012-08-30
DOI
10.1186/1479-5876-10-178
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis
- (2011) C. Mao et al. ANNALS OF ONCOLOGY
- Alterations in PTEN and PIK3CA in colorectal cancers in the EPIC Norfolk study: associations with clinicopathological and dietary factors
- (2011) Adam Naguib et al. BMC CANCER
- Mutations and epimutations in the origin of cancer
- (2011) Päivi Peltomäki EXPERIMENTAL CELL RESEARCH
- PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers
- (2011) Filip Janku et al. PLoS One
- Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases
- (2010) S. E. Baldus et al. CLINICAL CANCER RESEARCH
- Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: A meta-analysis of 22 studies
- (2010) Li-Xin Qiu et al. EUROPEAN JOURNAL OF CANCER
- Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
- (2010) Alberto Bardelli et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis
- (2010) Chen Mao et al. MOLECULAR BIOLOGY REPORTS
- Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy
- (2009) Milena Casula et al. BMC CANCER
- A role of BRCA1 and BRCA2germline mutations in breast cancer susceptibility within Sardinian population
- (2009) Grazia Palomba et al. BMC CANCER
- Distinct BRAF (V600E) and KRAS Mutations in High Microsatellite Instability Sporadic Colorectal Cancer in African Americans
- (2009) K. Kumar et al. CLINICAL CANCER RESEARCH
- Improving disease control in advanced colorectal cancer: Panitumumab and cetuximab
- (2009) Javier Rodríguez et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
- (2009) Arnaud D. Roth et al. JOURNAL OF CLINICAL ONCOLOGY
- BRAFMutation in Metastatic Colorectal Cancer
- (2009) Jolien Tol et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR
- (2008) Volker Heinemann et al. CANCER TREATMENT REVIEWS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More